CC
TBRA

Caxton Corporation’s Tobira Therapeutics, Inc. Common Stock TBRA Stock Holding History

Caxton Corporation’s Portfolio TBRA Stock Details TBRA Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2015
Q2 		– Sell
-1,259
Closed -$14K – 25
2015
Q1 		$14K Buy
+1,259
New +$13.5K 0.02% 20

Other funds holding TBRA

NHAS
Novo Holdings A/S Hellerup, Denmark $1.23B AUM 81.32% 1-Year Est. Return
BI
BVF Inc San Francisco, California $3.14B AUM 249.53% 1-Year Est. Return
CPV
Canaan Partners VII Westport, Connecticut $32.3M AUM 154.97% 1-Year Est. Return
A
Abingworth London, United Kingdom $307M AUM 93.47% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
SFM
Sphera Funds Management Tel Aviv, Israel $630M AUM 108.65% 1-Year Est. Return
Goldman Sachs
Goldman Sachs New York $871B AUM 31.28% 1-Year Est. Return
BFA
BlackRock Fund Advisors San Francisco, California $542B AUM 18.13% 1-Year Est. Return
Morgan Stanley
Morgan Stanley New York $1.66T AUM 25.57% 1-Year Est. Return
Millennium Management
Millennium Management New York $240B AUM 35.51% 1-Year Est. Return

Caxton Corporation's TBRA Position: Q2 2015 in Review

Caxton Corporation sold out of Tobira Therapeutics, Inc. Common Stock (TBRA) in Q2 2015, closing a stake of 1,259 shares — an estimated $14K sold.

Caxton Corporation first reported a position in TBRA in Q1 2015 and held it in 1 quarter. The position peaked at $14K in Q1 2015. 42 funds tracked by Wall St. Rank hold TBRA as of Q2 2015.

  • Caxton Corporation reported no remaining Tobira Therapeutics, Inc. Common Stock position as of Q2 2015 after selling out during the quarter.
  • Caxton Corporation sold 1,259 Tobira Therapeutics, Inc. Common Stock shares in Q2 2015, an estimated $14K.
  • Caxton Corporation first reported a position in Tobira Therapeutics, Inc. Common Stock in Q1 2015 and held it in 1 quarter.
  • Caxton Corporation's Tobira Therapeutics, Inc. Common Stock position peaked at $14K in Q1 2015.
  • 42 funds tracked by Wall St. Rank held Tobira Therapeutics, Inc. Common Stock as of Q2 2015.

Based on Caxton Corporation's 13F filing for Q2 2015, filed 14 Aug 2015.